The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

Imaging Competition voting is open!

by

Congratulations to the 12 participants whose images have been short listed for the calendar!

This competition was designed to acknowledge and encourage the creativity of our members involved in imaging studies. We had a fantastic turn out and thank all entries for your efforts.

We have short-listed 12 images which will made into a calendar for distribution by The Antibody Society at the Antibody Engineering & Therapeutics meeting in December. Congratulations!

But we would like you, our members and followers, to decide the winner.

The winning image will be featured as the cover image for the 2024 volume of mAbs and the cover image of the calendar. Additionally the member who submitted the winning image will receive broad exposure of their work, a $400 cash prize, and the option of a free registration to:
1) Schrödinger’s online course, Introduction to Computational Antibody Engineering; or
2) virtual or in-person Antibody Engineering & Therapeutics.

Click here to vote – polls are open until the 31st of July

The winner will be announced on the 1st of August!

Please see the short listed images below.

 

 

Imaging Competition voting is open!

by

Congratulations to the 12 participants whose images have been short listed for the calendar!

This competition was designed to acknowledge and encourage the creativity of our members involved in imaging studies. We had a fantastic turn out and thank all entries for your efforts.

We have short-listed 12 images which will made into a calendar for distribution by The Antibody Society at the Antibody Engineering & Therapeutics meeting in December. Congratulations!

But we would like you, our members and followers, to decide the winner.

The winning image will be featured as the cover image for the 2024 volume of mAbs and the cover image of the calendar. Additionally the member who submitted the winning image will receive broad exposure of their work, a $400 cash prize, and the option of a free registration to:
1) Schrödinger’s online course, Introduction to Computational Antibody Engineering; or
2) virtual or in-person Antibody Engineering & Therapeutics.

Click here to vote – polls are open until the 31st of July

The winner will be announced on the 1st of August!

Please see the short listed images below.

Call for papers: Attention Society members who are also authors!

by

mAbs is the official journal of The Antibody Society. Each year, the journal’s publisher, Taylor & Francis, provides several article publishing charge (APC) waivers, with a value of up to $4000 USD / £3200 / €3840 / $5570 AUD each, that we may distribute to members. To be considered for an APC waiver, please submit pre-submission inquiries, which should include the authors, title, abstract, and general outline of the intended article, to membership@antibodysociety.org.

mAbs publishes high quality reports, reviews, and perspective articles covering a range of antibody R&D topics, including:

  • Design, engineering, and selection of antibody therapeutics, including antibody-drug conjugates, multispecific antibodies, and single-domain antibodies
  • Machine learning and artificial intelligence applications
  • Non-clinical studies of antibodies, such as mechanism of action studies, safety, and efficacy studies in animals
  • Manufacturing and formulation
  • Regulatory review and approval of antibody therapeutics

The deadline for submission of the APC waiver request is July 31, 2023.

The deadline for submission of the manuscript to the journal is January 31, 2024.

The selected recipients will be notified as soon as possible after the request submission deadline.

Please contact Janice Reichert (janice.reichert@antibodysociety.org) if you have questions.

Further information:

mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus but serves a broad readership, including specialists in technology transfer, legal issues, investment, and the regulation of therapeutics.

The journal’s 2021 Impact Factor is 6.440 and, in total, articles are downloaded at a rate of over 1 million per year.

Members of The Antibody Society receive a 10% discount on article publication charges using their member code.

Computational Antibody Discovery Symposium now On Demand

by

Did you miss the Computational Antibody Discovery Symposium held on June 22?

On Demand videos are now available on YouTube!

  1. Introduction by Janice Reichert (The Antibody Society); Konrad Krawczyk (Natural Antibody); Andrew Buchanan (AstraZeneca), and
    the first speaker: Pietro Sormanni (University of Cambridge). Third-generation approaches of antibody discovery and optimization
  2. Tzvika Hartman (Biolojic Design). AI-driven design of smart therapeutics
  3. Sandeep Kumar (Boehringer Ingelheim). Biopharmaceutical Informatics: Syncretic use of computation and experimentation in discovery and development of biotherapeutics
  4. Ben Holland (Antiverse). Machine learning-based design of antibodies against difficult targets
  5. Panel discussion summary: Panelists provided their opinions and insights on these questions:
    What properties are more urgent to be able to design in silico – binding specificity, developability or something else?
    What performance should computational antibody design achieve to improve upon established protocols?
    What are the biggest hurdles for computational antibody discovery to achieve its full potential (models, data or something else)?
    How could industry and academia complement each other to solve the problem of computationally designing antibodies?
    What role does big tech/biopharma have to play in development and adoption of computational antibody design paradigms?
  6. Concluding remarks (Andrew Buchanan, AstraZeneca)

The complete playlist is here.

Please note: Victor Greiff presented unpublished material; posting of the video of his talk will be delayed. Please subscribe to our YouTube channel to receive an alert when new videos are added.

Thank you for your interest in the Symposium. We hope the videos inspire useful discussions in the future.

RYSTIGGO® (rozanolixizumab-noli) approved by FDA

by

On June 27, 2023, the US Food and Drug Administration approved RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive. Rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor, resulting in the reduction of circulating IgG. The drug is administered by subcutaneous infusion. UCB has indicated that rozanolixizumab-noli will be commercially available in the US during the 3rd quarter of 2023.

FDA’s approval is supported by safety and efficacy data from the pivotal Phase 3 MycarinG study (NCT03971422), published in The Lancet Neurology in May 2023. The primary efficacy endpoint was the comparison of the change from baseline between treatment groups in the MG-ADL total score at day 43. MG-ADL is a measurement tool which assesses the impact of gMG on daily functions of 8 signs or symptoms that are typically affected in gMG, such as breathing, talking, swallowing, and being able to rise from a chair. Each item is assessed on a 4-point scale where a score of 0 represents normal function and a score of 3 represents loss of ability to perform that function. A total score ranges from 0 to 24, with the higher scores indicating more impairment. A statistically significant difference favoring rozanolixizumab-noli was observed in the MG-ADL total score change from baseline [-3.4 points in rozanolixizumab-noli-treated group at either dose vs -0.8 points in the placebo-treated group (p<0.001)].

Interested in data for other antibody therapeutics that have received marketing authorizations? Go to our searchable table of approved antibody therapeutics and those in regulatory review for more information.